证券代码：300653 证券简称：正海生物 烟台正海生物科技股份有限公司 投资者关系活动记录表 编号：2020006 | --- | --- | --- | --- | |--------------------------|------------------------------|-----------------------------------------------------------------------|-------| | 投资者关系 \n活动类别 | √ \n□ \n□ 现场参观 □其他 | 特定对象调研 □媒体采访 □分析师会议 \n新闻发布会 □业绩说明会 □路演活动 | | | 参与单位 名称及人员 姓名 | 德邦证券：张騄、袁之渿、余曦 | | | | 时 间 | 2020 年 9 月 21 | 日下午 4:00-5:30 | | | | | | | | 地 点 | | 烟台正海生物科技股份有限公司会议室 | | | 上市公司 | 董事长：王涛先生 | | | | 接待人员 姓名 | | 副总经理、董事会秘书：陆美娇女士 | | | | | 投资者关系活动主要内容 | | ...

Financial Performance - In 2018, the company achieved product sales revenue of CNY 216 million, a year-on-year increase of 17.92% [2] - The total sales volume reached 268,800 units, reflecting a growth of 45.67% compared to the previous year [2] - The net profit attributable to shareholders was approximately CNY 85.82 million, marking a 39.15% increase year-on-year [2] Product Sales Overview - Sales revenue from oral repair membranes grew by 21.22% year-on-year, with sales volume increasing by 51.10% [2] - Sales revenue from bone repair materials exceeded CNY 11.19 million, accounting for over 5% of total revenue [3] Inventory and Market Strategy - The increase in inventory levels in 2018 and Q1 2019 was due to enhanced market development efforts and rising market demand [2] - The company aims to ensure market supply by increasing inventory quantities [2] R&D and Product Development - Active biological bone has been accepted by the National Medical Products Administration in November 2018 and is currently under priority review [2] - Ongoing R&D projects include materials for endometrial repair and various other medical applications [2][3] Sales Channels and Profit Margins - In 2018, distribution accounted for approximately 70% of sales with a gross margin of 91.8%, while direct sales made up nearly 30% with a gross margin of 96.1% [3] Future Plans and Strategic Vision - The company aims to be a leader in the field of regenerative medicine, focusing on the industrialization of biological regenerative materials [3] - Plans for 2019 include enhancing management precision, strengthening marketing teams, and accelerating new product development [4]

证券代码：300653 证券简称：正海生物 烟台正海生物科技股份有限公司 投资者关系活动记录表 编号：2019002 | --- | --- | --- | --- | |-------------------|----------------------------------------------------------|-------------------------------------------------|----------------------------------------------------------------------| | | | | | | | þ | 特定对象调研 □媒体采访 □分析师会议 | | | 投资者关系 | □ | 新闻发布会 □业绩说明会 □路演活动 | | | 活动类别 | □ 现场参观 □其他： | | | | 参与单位 | | | 富国基金 娄圣睿，莫尼塔信息咨询 张静含，景林资产 沈一洲，银杏 | | 名称及人员 姓名 | | 谷投资 熊适时，东兴证券 胡博新，个人投资者 闫祺 | | | 时 间 | 2019 年 5 月 28 | 日 ...

Group 1: Company Performance and Projections - The company expects to disclose its performance for the first half of 2018 in the upcoming semi-annual report, with preliminary results already shared in the Q1 report [1] - The growth in the oral repair membrane market is primarily driven by an increase in patients in the maxillofacial surgery field and rapid growth in the implant market [2] Group 2: Inventory and Sales Model - The current inventory turnover rate is considered reasonable compared to other listed companies in the industry [2] - The company's sales model combines direct sales and distribution, with a notable increase in distribution revenue due to expanded distribution networks and centralized procurement by hospital clients [2] Group 3: Market and Capacity - The main sales coverage areas are oral-related departments and neurosurgery, which are currently stable, with ongoing efforts to expand sales [2] - The company has flexible production capacity that can be adjusted based on market demand, ensuring that capacity will not become a limiting factor [2] Group 4: Investment Projects and R&D - The planning for the fundraising project construction land has been completed, and the project is actively progressing [2] - The "active biological bone" project is progressing smoothly, with timely updates expected upon submission of the registration application [2] - The purpose of the regenerative membrane in R&D projects is to guide bone tissue regeneration in the oral field, aligning with current oral channels [2] Group 5: Collaboration with Research Institutions - The company maintains an open attitude towards collaboration with external research institutions, with stable relationships with existing partners [2]

证券代码：300653 证券简称：正海生物 烟台正海生物科技股份有限公司 投资者关系活动记录表 编号：2018001 | --- | --- | --- | |---------------------|------------------------------------|---------------------------------------------------------------| | | þ | 特定对象调研 □媒体采访 □分析师会议 | | 投资者关系 | □ | 新闻发布会 □业绩说明会 □路演活动 | | 活动类别 | □ 现场参观 □其他： | | | | | 平安证券 叶寅、韩盟盟，安信证券 周新明，国海证券 胡博新 | | | | 招商证券 漆经纬，凯石基金 盛夏，博时基金 葛晨，华宝基金 杨钊 | | 参与单位 名称及人员 | | 浦银安盛基金 刘诗瑶，高毅资产 冯鹏，万杉资本 许均华，汐泰投资 | | 姓名 | | 冯时，东方马拉松投资 王攀峰，阿特夏木投资 徐曼，首善财富 杨正 | | | | 志、徐迅捷，宇轩创富 陆世明、何亚龙，渝辰投资 彭阳 | | 时 间 | ...

证券代码：300653 证券简称：正海生物 烟台正海生物科技股份有限公司 投资者关系活动记录表 编号：2020008 | --- | --- | --- | --- | |--------------------------|--------------------------------------|-----------------------------------------------------------------------|----------------------------------------------------------| | 投资者关系 \n活动类别 | √ \n□ \n□ 现场参观 □其他 | 特定对象调研 □媒体采访 □分析师会议 \n新闻发布会 □业绩说明会 □路演活动 | | | 参与单位 名称及人员 姓名 | | | 徐星投资 张东伟、毛丽丽，长城证券 穆云吉，莲盛投资 游艺 | | 时 间 | 2020 年 12 月 30 | 日 14:00-16:00 | | | | | | | | 地 点 | 公司会议室 | | | | 上市公司 | 董事长 王涛先生 ...

证券代码：300653 证券简称：正海生物 烟台正海生物科技股份有限公司 投资者关系活动记录表 编号：2021001 | --- | --- | --- | |---------------------------|---------------------------------------------------------------------------------------------------------|--------------------------| | | □特定对象调研 | □媒体采访 □分析师会议 | | 投资者关系 活动类别 | □新闻发布会 □业绩说明会 | □路演活动 | | | □现场参观 √其他 ：电话会议 | | | | 平安证券 韩盟盟；中泰自营 彭婷、潘冬；中泰证券 中科沃土 孟禄程；信达澳银 李典点；光大控股 | 王鑫； 徐德仁； | | | 凯石基金 朱亮；劲邦资本 孙颖；华泰自营 田野； | | | 参与单位 | | | | 名称及人员 姓名 | 君正资本 戴泽龙；宝盈基金 杨明隽；工银瑞信 | 李乾宁； | | | 平安养老 陶歆蔚；平安证券 李平；榕 ...

证券代码：300653 证券简称：正海生物 烟台正海生物科技股份有限公司 投资者关系活动记录表 编号：2021007 | --- | --- | --- | |----------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------| | | □特定对象调研 | □媒体采访 □分析师会议 | | 投资者关系 活动类别 | □新闻发布会 □业绩说明会 | □路演活动 | | | □现场参观 √其他: 电话会 | | | | | ...

证券代码：300653 证券简称：正海生物 烟台正海生物科技股份有限公司 投资者关系活动记录表 编号：2021006 | --- | --- | --- | --- | --- | |--------------------------|-------|--------------------------|----------------------------------------------------------------------|-----------------------------------| | 投资者关系 活动类别 | | √特定对象调研 | \n□新闻发布会 □业绩说明会 \n□现场参观 □其他 | □媒体采访 □分析师会议 \n□路演活动 | | 参与单位 名称及人员 姓名 | | 瑞华投资 | 张小兵；景泰利丰投资 邹因素；中信证券 | 黄耀庭 | | 时 间 | | 2021 年 5 月 17 | 日 上午 09:00-10:00 | | | 上市公司 | | 地 点 公司会议室 | | | | 接待人员 姓名 | | | 副总经理、董事会秘书：陆美娇女士 | | | | ...

华西证券 崔文亮、谭国超；平安证券 叶寅、韩盟盟； 太平洋证券 盛丽华、谭紫媚；广发证券 漆经纬；大成基金 陈泉龙； 参与单位 名称及人员 姓名 国泰基金 赵大震；恒生前海 鲁娜；华安基金 王春； 工银瑞信 李善欣；泰达宏利 赖庆鑫；天弘基金 张秀磊； 银华基金 秦锋等 63 位机构投资者 证券代码：300653 证券简称：正海生物 烟台正海生物科技股份有限公司 投资者关系活动记录表 编号：2021004 | --- | --- | --- | --- | |-----------------------|-------------------------|-----------------------|-----------| | | | | | | | □特定对象调研 | □媒体采访 □分析师会议 | | | 投资者关系 活动类别 | □新闻发布会 □业绩说明会 | | □路演活动 | | | □现场参观 √其他 | ：电话会议 | | | --- | --- | --- | |-------------------------|--------------|----------------------- ...